Altimmune's IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis demonstrates pemvidutide's favorable tolerability, with fewer discontinuations due to adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback